Coagulopathy in COVID-19 differs from usual disseminated intravascular coagulation by having elevated fibrinogen, normal or slightly prolonged prothrombin time, and activated partial thromboplastin time, with a platelet count > 100 × 103/mL, but no significant bleeding [37]. This evidence concerns the gene F2 and COVID-19.